One Carbon Therapeutics AB

One-carbon Therapeutics is a clinical-stage precision oncology company based in Solna, Sweden, that specializes in developing novel cancer therapies. The company focuses on targeting one-carbon metabolism pathways, specifically through the inhibition of MTHFD1 and MTHFD2 proteins. By leveraging a deep understanding of cancer biology and DNA repair processes, they have developed TH9619, a first-in-class small-molecule inhibitor designed to induce toxic folate trapping in cancer cells. This mechanism starves tumors of thymidine, a critical DNA building block, leading to DNA damage and cancer cell death, while aiming to improve tolerability for patients compared to traditional therapies.

The company is currently engaged in clinical development, including the ODIN Phase 1/2 study, to evaluate the safety and efficacy of its therapeutic approaches in patients with advanced solid tumors. To support its research and clinical milestones, One-carbon Therapeutics has secured significant private financing and entered into strategic collaborations, such as a partnership with Tempus AI, to utilize multimodal data and bioinformatics in its drug development pipeline. These efforts are aimed at translating sophisticated metabolic science into transformative, cancer-specific treatments for patients globally.